ArticleHepatology communications2026
Hepatitis B treatment response and factors associated with HBV treatment success: A population-based study in Rwanda.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTimely treatment of chronic hepatitis B virus (HBV) infection reduces complications such as cirrhosis and hepatocellular carcinoma and improves overall survival. In Sub-Saharan Africa, data on HBV treatment success are limited, especially among people living with HBV mono-infection. We assessed the success of HBV treatment and associated factors among people diagnosed with HBV mono-infection and HIV co-infection.
methodsWe used data from the District Health Information System 2 in Rwanda, covering 4.6 million screened individuals (January 2016-June 2023). Patients receiving HBV therapy for ≥12 months were included. Treatment success was defined as undetectable HBV DNA or normal ALT at 12 months. We used multilevel logistic regression to assess risk factors, accounting for clustering by hospital.
resultsAmong 4733 treated individuals (median age: 39 y, 58.4% male), 4518 (95.5%) achieved treatment success, increasing over time (90.3% for <2 y vs. 95.8% for ≥2 y of follow-up). Treatment success was mostly assessed by ALT normalization (87.5%). HBV mono-infected and HBV/HIV co-infected individuals had similar overall treatment success rates [3730 (95.5%) vs. 788 (95.2%)]. However, among those treated for <2 years, success was lower in HBV/HIV individuals [7 (43.8%) vs. 283 (92.7%)]. In multivariable analysis, HCV co-infection (aOR: 0.33; 95% CI: 0.12, 0.85), follow-up at provincial/referral hospitals (aOR: 0.26; 95% CI: 0.08, 0.86), and cirrhosis (aOR: 0.36; 95% CI: 0.20, 0.63) were associated with a lower likelihood of HBV treatment success.
conclusionsHBV treatment success in Rwanda was high but lower in those with HBV/HCV co-infection or cirrhosis, underscoring the need for early detection and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.